May 16 (Reuters) - Can Fite Biopharma Ltd CANF.TA
* Can-Fite files clinical trial application in canada for piclidenoson ahead of upcoming acrobat rheumatoid arthritis phase iii study
* Can fite biopharma ltd says intends to commence its phase iii acrobat trial of piclidenoson in treatment of rheumatoid arthritis in q2 of 2017
* Can fite biopharma ltd - can-fite intends to commence its phase iii acrobat trial of piclidenoson in treatment of rheumatoid arthritis in q2 of 2017. Source text for Eikon: ID:nPnZz6Sra Further company coverage: CANF.TA